摘要
目的:比较培美曲塞联合顺铂与多西紫杉醇联合顺铂(TP)方案治疗晚期非小细胞肺癌(NSCLC)的疗效及不良反应。方法:晚期NSCLC患者55例随机分成两组:培美曲塞联合顺铂组26例,TP组29例,两组均完成2个周期以上化疗。结果:培美曲塞联合顺铂组有效率为30.8%,TP组有效率为31.0%,两组近期有效率差异无统计学意义(P>0.05)。培美曲塞联合顺铂组白细胞减少及脱发发生率明显低于TP组(P<0.05),两组恶心、呕吐、血小板减少、肝功能受损、贫血、皮疹等不良反应无明显差异(P>0.05)。结论:培美曲塞联合顺铂方案治疗晚期NSCLC与TP方案的疗效相当,但不良反应相对较轻,可以作为临床一线方案推广。
Objective:To compare the efficiency of TP and pemetrexed plus cisplatin for advanced non-small cell lung cancer.Methods:Fifty-five patients with advanced NSCLC were randomly divided into pemetrexed plus cisplatin group(26 cases) and TP group(29 cases).The two groups underwent two courses of chemotherapy of pemetrexed plus cisplatin and TP regime respectively.Results:The effective rate of pemetrexed plus cisplatin group was 30.8% while that of TP group was 31.0%,the recent efficiency of the two groups was not significant different(P0.05).But incidence of white blood cell decrease and hair loss were significantly lower in pemetrexed plus cisplatin group than that in TP Group(P0.05).There were no significantly difference in incidence of nausea,vomiting,decreased platelets,liver function impairment and anemia(P0.05).Conclusions:Pemetrexed plus cisplatin shows comparable effects on NSCLC as TP regime,while the side effects were lighter than the latte.
出处
《海南医学院学报》
CAS
2012年第1期45-47,共3页
Journal of Hainan Medical University
基金
海南医学院科研基金资助学报项目(0020120012)~~
关键词
非小细胞肺癌
培美西塞
多西紫杉醇
顺铂
化疗
Non-small cell lung cancer
Pemetrexed
Docetaxel
Cisplatin
Chemotherapy